Literature DB >> 1515377

Scanning eye movements in schizophrenic patients. Relationship to clinical symptoms and regional cerebral blood flow using 123I-IMP SPECT.

M Tsunoda1, M Kurachi, S Yuasa, Y Kadono, M Matsui, A Shimizu.   

Abstract

Eye movements during the Benton Visual Retention Test were examined using an eye-mark recorder in 32 schizophrenic patients and 32 normal controls. The patients had significantly fewer eye fixations, longer mean duration of fixation and shorter length of mean scan path than the controls. In the patients, these eye movement parameters were significantly correlated with the negative symptom score but not with the positive symptom score on the Positive and Negative Syndrome Scale. These parameters had a significant correlation with the composite score on the Scale for the Assessment of Negative Symptoms (SANS). In particular, they were highly correlated with avolition-apathy and affective flattening or blunting scores on SANS subscales. Thus, examination of scanning eye movements seemed to be a good objective index of negative symptoms. Secondly, regional cerebral blood flow (rCBF) was examined using N-isopropyl-p-[123I]iodoamphetamine (123I-IMP) and single photon emission computer tomography in 17 of 32 patients. With regard to the relationship between the eye movement parameters and rCBF, the mean duration of fixation was negatively correlated with 123I-IMP uptake in the left superior frontal area and left basal ganglia. The mean length of the scan path was correlated with uptake in the left superior frontal area. These findings suggest that the characteristic eye movements of schizophrenic patients are likely to be related with dysfunction of the frontal-basal ganglia neural circuit.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1515377     DOI: 10.1016/0920-9964(92)90046-8

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

1.  Relationship between exploratory eye movements and brain morphology in schizophrenia spectrum patients: voxel-based morphometry of three-dimensional magnetic resonance imaging.

Authors:  Masahiko Tsunoda; Yasuhiro Kawasaki; Mie Matsui; Yasuhiro Tonoya; Hirofumi Hagino; Michio Suzuki; Hikaru Seto; Masayoshi Kurachi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

Review 2.  Atypical scanpaths in schizophrenia: evidence of a trait- or state-dependent phenomenon?

Authors:  Sara A Beedie; Philip J Benson; David M St Clair
Journal:  J Psychiatry Neurosci       Date:  2011-05       Impact factor: 6.186

Review 3.  A pathophysiological approach to saccadic eye movements in neurological and psychiatric disease.

Authors:  C Kennard; T J Crawford; L Henderson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

4.  Saccadic eye movements and regional cerebral blood flow in schizophrenic patients.

Authors:  M Matsui; M Kurachi; S Yuasa; M Aso; Y Tonoya; S Nohara; O Saitoh
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

5.  Impaired saccadic eye movements on stationary targets in patients with schizophrenia spectrum disorder.

Authors:  M Matsui; M Kurachi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

6.  Contextual perception under active inference.

Authors:  M Berk Mirza; Maell Cullen; Thomas Parr; Sukhi Shergill; Rosalyn J Moran
Journal:  Sci Rep       Date:  2021-08-10       Impact factor: 4.379

7.  Eye movement characteristics in male patients with deficit and non-deficit schizophrenia and their relationships with psychiatric symptoms and cognitive function.

Authors:  Lin Zhang; Xiangrong Zhang; Xinyu Fang; Chao Zhou; Lu Wen; Xinming Pan; Fuquan Zhang; Jiu Chen
Journal:  BMC Neurosci       Date:  2021-11-24       Impact factor: 3.288

8.  Basal ganglia neuronal activity during scanning eye movements in Parkinson's disease.

Authors:  Tomáš Sieger; Cecilia Bonnet; Tereza Serranová; Jiří Wild; Daniel Novák; Filip Růžička; Dušan Urgošík; Evžen Růžička; Bertrand Gaymard; Robert Jech
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.